PT-141 and the Melanocortin System
PT-141 (bremelanotide) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that has been investigated in preclinical research for its activity at melanocortin receptors, particularly MC3R and MC4R. The melanocortin system is a family of five G-protein-coupled receptors (MC1R-MC5R) that mediate diverse physiological functions, making it an active area of receptor pharmacology research.
Receptor Pharmacology
PT-141 acts as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. In preclinical research, its effects at MC4R have been of particular interest due to this receptor's expression in the central nervous system, including the hypothalamus, where it participates in multiple neuroendocrine signaling pathways investigated in laboratory settings.
Central Nervous System Research
The melanocortin system has been investigated in preclinical models for roles in energy homeostasis, neuroendocrine regulation, and behavioral pathways. MC4R activation has been studied for its downstream effects on oxytocin and dopamine signaling in animal models, contributing to understanding of hypothalamic neuropeptide interactions.
Structural Features
PT-141 was derived from the linear peptide melanotan II through removal of the C-terminal amide. Its cyclic structure confers enhanced metabolic stability compared to linear melanocortin peptides, making it a useful pharmacological tool for receptor characterization studies.
Explore ROEHN's research compound catalog, including complementary peptides for neuroendocrine research like BPC-157 and CJC-1295/Ipamorelin.
Research Disclaimer
This article is for educational and informational purposes only. All compounds discussed are intended strictly for in-vitro and preclinical research use. They are not intended for human consumption. Always consult published scientific literature and institutional review protocols before initiating any research program.